350 related articles for article (PubMed ID: 28755409)
1. A first-in-human pharmacodynamic and pharmacokinetic study of a fully human anti-glucagon receptor monoclonal antibody in normal healthy volunteers.
Kostic A; King TA; Yang F; Chan KC; Yancopoulos GD; Gromada J; Harp JB
Diabetes Obes Metab; 2018 Feb; 20(2):283-291. PubMed ID: 28755409
[TBL] [Abstract][Full Text] [Related]
2. Glucagon Receptor Blockade With a Human Antibody Normalizes Blood Glucose in Diabetic Mice and Monkeys.
Okamoto H; Kim J; Aglione J; Lee J; Cavino K; Na E; Rafique A; Kim JH; Harp J; Valenzuela DM; Yancopoulos GD; Murphy AJ; Gromada J
Endocrinology; 2015 Aug; 156(8):2781-94. PubMed ID: 26020795
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and pharmacodynamic modeling of a monoclonal antibody antagonist of glucagon receptor in male ob/ob mice.
Lau YY; Ma P; Gibiansky L; Komorowski R; Wang J; Wang G; Yan H; Véniant MM; Kakkar T
AAPS J; 2009 Dec; 11(4):700-9. PubMed ID: 19851873
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 after single subcutaneous administration in healthy subjects.
Portron A; Jadidi S; Sarkar N; DiMarchi R; Schmitt C
Diabetes Obes Metab; 2017 Oct; 19(10):1446-1453. PubMed ID: 28741871
[TBL] [Abstract][Full Text] [Related]
5. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
6. Single and multiple ascending-dose study of glucagon-receptor antagonist RN909 in type 2 diabetes: a phase 1, randomized, double-blind, placebo-controlled trial.
Gumbiner B; Esteves B; Dell V; Joh T; Garzone PD; Forgie A; Udata C
Endocrine; 2018 Nov; 62(2):371-380. PubMed ID: 30203123
[TBL] [Abstract][Full Text] [Related]
7. Effects of multiple ascending doses of the glucagon receptor antagonist PF-06291874 in patients with type 2 diabetes mellitus.
Kazierad DJ; Bergman A; Tan B; Erion DM; Somayaji V; Lee DS; Rolph T
Diabetes Obes Metab; 2016 Aug; 18(8):795-802. PubMed ID: 27059951
[TBL] [Abstract][Full Text] [Related]
8. Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes.
Kelly RP; Garhyan P; Raddad E; Fu H; Lim CN; Prince MJ; Pinaire JA; Loh MT; Deeg MA
Diabetes Obes Metab; 2015 Apr; 17(4):414-22. PubMed ID: 25656305
[TBL] [Abstract][Full Text] [Related]
9. Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes: A randomized controlled trial.
Pettus J; Reeds D; Cavaiola TS; Boeder S; Levin M; Tobin G; Cava E; Thai D; Shi J; Yan H; Bautista E; McMillan J; Unger R; Henry RR; Klein S
Diabetes Obes Metab; 2018 May; 20(5):1302-1305. PubMed ID: 29283470
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study.
Xu Z; Bouman-Thio E; Comisar C; Frederick B; Van Hartingsveldt B; Marini JC; Davis HM; Zhou H
Br J Clin Pharmacol; 2011 Aug; 72(2):270-81. PubMed ID: 21392075
[TBL] [Abstract][Full Text] [Related]
11. First proof of pharmacology in humans of a novel glucagon receptor antisense drug.
van Dongen MG; Geerts BF; Morgan ES; Brandt TA; de Kam ML; Romijn JA; Cohen AF; Bhanot S; Burggraaf J
J Clin Pharmacol; 2015 Mar; 55(3):298-306. PubMed ID: 25197025
[TBL] [Abstract][Full Text] [Related]
12. LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects.
Barrington P; Chien JY; Tibaldi F; Showalter HD; Schneck K; Ellis B
Diabetes Obes Metab; 2011 May; 13(5):434-8. PubMed ID: 21251179
[TBL] [Abstract][Full Text] [Related]
13. MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 study.
Ambery PD; Klammt S; Posch MG; Petrone M; Pu W; Rondinone C; Jermutus L; Hirshberg B
Br J Clin Pharmacol; 2018 Oct; 84(10):2325-2335. PubMed ID: 29926478
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
[TBL] [Abstract][Full Text] [Related]
15. Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study.
Irie S; Matsumura Y; Zdravkovic M; Jacobsen LV; Kageyama S
Int J Clin Pharmacol Ther; 2008 Jun; 46(6):273-9. PubMed ID: 18541123
[TBL] [Abstract][Full Text] [Related]
16. Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study.
Xu H; Sheng L; Chen W; Yuan F; Yang M; Li H; Li X; Choi J; Zhao G; Hu T; Li Y; Zhang Y; Chen L
Drug Des Devel Ther; 2016; 10():1619-26. PubMed ID: 27274195
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and pharmacodynamic characteristics of single-dose Canakinumab in patients with type 2 diabetes mellitus.
Noe A; Howard C; Thuren T; Taylor A; Skerjanec A
Clin Ther; 2014 Nov; 36(11):1625-37. PubMed ID: 25240532
[TBL] [Abstract][Full Text] [Related]
19. A 4-week study assessing the pharmacokinetics, pharmacodynamics, safety, and tolerability of the glucagon receptor antagonist PF-06291874 administered as monotherapy in subjects with type 2 diabetes mellitus.
Bergman A; Tan B; Somayaji VR; Calle RA; Kazierad DJ
Diabetes Res Clin Pract; 2017 Apr; 126():95-104. PubMed ID: 28237861
[TBL] [Abstract][Full Text] [Related]
20. Safety, Tolerability, Pharmacokinetics, and Immunogenicity of the Anti-IFNAR1 Monoclonal Antibody QX006N: A First-in-Human Single Ascending Dose Study in Healthy Chinese Volunteers.
Li X; Li B; Wang M; Fang M; Lou J; Liu J; Chen H; Ding Y
BioDrugs; 2024 Mar; 38(2):313-321. PubMed ID: 38148466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
